SAWC

MediWound Reports First Quarter 2024 Financial Results and Provides Company Update

Retrieved on: 
星期三, 五月 29, 2024
Wound, Patient, GMP, Research and development, Hospital, Burn, Tax, European Wound Management Association, Eastern Time Zone, Food, Supplement, SAWC, CAPEX, HERE, Exercise, FDA, Therapy, Bank statement, Expanded access, Forecasting, EWMA, Event, WHS, Depreciation, Operating cost, Symposium, BLA, Research, Table, Adjustment, NEXT, Bromelain (pharmacology), Pharmaceutical industry

Revenue: Revenue for the first quarter of 2024 was $5.0 million, compared to $3.8 million in the first quarter of 2023.

Key Points: 
  • Revenue: Revenue for the first quarter of 2024 was $5.0 million, compared to $3.8 million in the first quarter of 2023.
  • Research and Development: R&D expenses in the first quarter of 2024 were $1.5 million, compared to $2.1 million in the first quarter of 2023.
  • Operating Results: Operating loss in the first quarter of 2024 was $3.7 million, compared to an operating loss of $4.4 million in the first quarter of 2023.
  • During the first quarter of 2024, the Company received $0.5 million from the exercise of Series A warrants.

Kerecis to Present Scientific and Clinical Updates on Fish-Skin Grafts at the Symposium on Advanced Wound Care Spring

Retrieved on: 
星期二, 五月 14, 2024
Surgery, Medical Devices, Hospitals, Health Technology, Stem Cells, Biotechnology, Other Health, Health, General Health, Patient, Mohs surgery, FNP, SAWC, Achilles tendon, Skin, DPM, Dicarboxylic acid, Research, WOCN, Regenerative medicine, Abstract, Multimedia, Foot, Female

Kerecis , the pioneer in the use of fish skin and fatty acids for tissue regeneration and protection, will unveil its latest scientific and clinical updates, including trial results, at the upcoming Symposium on Advanced Wound Care (SAWC) Spring.

Key Points: 
  • Kerecis , the pioneer in the use of fish skin and fatty acids for tissue regeneration and protection, will unveil its latest scientific and clinical updates, including trial results, at the upcoming Symposium on Advanced Wound Care (SAWC) Spring.
  • Kerecis will exhibit at booth 419 at SAWC, which will take place from May 14 to 18 in Orlando, Florida.
  • “Our ongoing research and data underscore significantly improved healing times, reduced complications, and enhanced patient outcomes across different clinical settings.
  • During a hands-on skills lab, Kerecis medical affairs program managers will demonstrate Kerecis products, highlighting advanced applications in real-world clinical settings.

MolecuLight Clinical Research Featured at the Upcoming SAWC Spring 2024 Conference

Retrieved on: 
星期二, 五月 14, 2024
Patient, DX, Fluorescence imaging, Exhibition, Evaluation, General number field sieve, CLASS, SAWC, Education, Pyoderma, FDA, Effectiveness, Publication, Infection, Antibiotic, Madigan Army Medical Center, Symposium, ASC, Pyoderma gangrenosum, Fluorescence, Medical imaging

Notably, one of these posters, recognized as the top-scoring abstract, introduces an innovative upcoming device feature: thermal imaging.

Key Points: 
  • Notably, one of these posters, recognized as the top-scoring abstract, introduces an innovative upcoming device feature: thermal imaging.
  • The international conference, taking place from May 14 - 18, 2024, in Orlando, Florida, stands as one of the largest multidisciplinary meetings of wound care professionals globally.
  • In addition to the clinical posters and presentations at SAWC Spring 2024 , the MolecuLight i:X® and DX™ imaging devices will be available for demonstration in the MolecuLight booth #312 in the Exhibition Hall.
  • With unmatched clinical evidence including 95 peer-reviewed publications with over 3000 patients, they are used by leading wound care facilities globally.

MolecuLight Clinical Research Featured at the Upcoming SAWC Spring 2024 Conference

Retrieved on: 
星期二, 五月 14, 2024
Patient, DX, Fluorescence imaging, Exhibition, Evaluation, General number field sieve, CLASS, SAWC, Education, Pyoderma, FDA, Effectiveness, Publication, Infection, Antibiotic, Madigan Army Medical Center, Symposium, ASC, Pyoderma gangrenosum, Fluorescence, Medical imaging

TORONTO and ORLANDO, Fla., May 14, 2024 /PRNewswire/ -- - MolecuLight Inc., the pioneer in point-of-care fluorescence imaging for real-time detection of elevated bacterial loads in wounds, proudly announces the presentation of findings from multiple MolecuLight studies in nine clinical posters at the Symposium on Advanced Wound Care (SAWC) Spring 2024. These studies feature new data demonstrating enhanced diagnostics, targeted debridement, improved healing outcomes, and increased patient engagement facilitated by MolecuLight devices. Notably, one of these posters, recognized as the top-scoring abstract, introduces an innovative upcoming device feature: thermal imaging. The international conference, taking place from May 14 - 18, 2024, in Orlando, Florida, stands as one of the largest multidisciplinary meetings of wound care professionals globally.

Key Points: 
  • Notably, one of these posters, recognized as the top-scoring abstract, introduces an innovative upcoming device feature: thermal imaging.
  • The international conference, taking place from May 14 - 18, 2024, in Orlando, Florida, stands as one of the largest multidisciplinary meetings of wound care professionals globally.
  • In addition to the clinical posters and presentations at SAWC Spring 2024 , the MolecuLight i:X® and DX™ imaging devices will be available for demonstration in the MolecuLight booth #312 in the Exhibition Hall.
  • With unmatched clinical evidence including 95 peer-reviewed publications with over 3000 patients, they are used by leading wound care facilities globally.

SmartTRAK Launches New Site-of-Care Treatment Tracker for Wound Care Powered by Data Partnership with Intellicure Analytics

Retrieved on: 
星期一, 五月 13, 2024
Partnership, SAWC, History, Regenerative medicine, Symposium, GM, Consultant, Nursing

IRVINE, Calif., May 13, 2024 /PRNewswire-PRWeb/ -- SmartTRAK, the leading Medtech market and business intelligence solution in Orthopedics, Wound Care, Regenerative Medicine and Neuro Therapies, in partnership with Intellicure Analytics announces the release of SmartTRAK Treatment Tracker, an innovative tool that provides in-depth market data and trending analytics across wound care treatments by site of care. The first offering in the data solutions portfolio is available now and covers the usage of Skin Substitutes in the hospital outpatient department (HOPD).

Key Points: 
  • New offering delivers wound care companies with actionable data and analytics on wound care treatments, products and brands by site of care.
  • IRVINE, Calif., May 13, 2024 /PRNewswire-PRWeb/ -- SmartTRAK, the leading Medtech market and business intelligence solution in Orthopedics, Wound Care, Regenerative Medicine and Neuro Therapies, in partnership with Intellicure Analytics announces the release of SmartTRAK Treatment Tracker , an innovative tool that provides in-depth market data and trending analytics across wound care treatments by site of care.
  • "Wound care companies are in need of organized, easily accessible insights related to wound care treatments by site of care to drive their growth strategies," says Susan Paquette, VP/GM of SmartTRAK Wound Care.
  • "Wound care companies are in need of organized, easily accessible insights related to wound care treatments by site of care to drive their growth strategies," says Susan Paquette, VP/GM of SmartTRAK Wound Care.

Arch Therapeutics to Present AC5® Advanced Wound System at the 2024 Symposium on Advanced Wound Care Spring Meeting (SAWC Spring)

Retrieved on: 
星期一, 五月 6, 2024
Chin Na, OTCQB, Food, Symposium, AC5, Patient, SAWC, Human, Wound healing, Therapy, Orlando World Center Marriott, User experience, Nursing

FRAMINGHAM, Mass., May 06, 2024 (GLOBE NEWSWIRE) -- Arch Therapeutics, Inc. (OTCQB: ARTH) (“Arch” or the “Company”), a marketer and developer of novel self-assembling wound care and biosurgical products, today announced that the Company’s first commercial product, AC5® Advanced Wound System (“AC5”), will be featured at the 2024 Symposium on Advanced Wound Care Spring Meeting (“SAWC Spring”), which takes place at Orlando Marriott World Center, Orlando, from May 14-18, 2024.

Key Points: 
  • FRAMINGHAM, Mass., May 06, 2024 (GLOBE NEWSWIRE) -- Arch Therapeutics, Inc. (OTCQB: ARTH) (“Arch” or the “Company”), a marketer and developer of novel self-assembling wound care and biosurgical products, today announced that the Company’s first commercial product, AC5® Advanced Wound System (“AC5”), will be featured at the 2024 Symposium on Advanced Wound Care Spring Meeting (“SAWC Spring”), which takes place at Orlando Marriott World Center, Orlando, from May 14-18, 2024.
  • Arch’s team will be available for discussions with clinicians throughout the Symposium and at Arch’s booth (#535) in the exhibit hall.
  • Terrence W. Norchi, MD, President and CEO of Arch Therapeutics, said, “We are delighted that AC5 Advanced Wound System will be presented again at this important Symposium.
  • AC5 is a synthetic self-assembling wound care product that provides clinicians with multi-modal support and utility across all phases of wound healing.

MediWound to Present New Data from EscharEx® Phase II Studies at Three Leading Wound Care Conferences

Retrieved on: 
星期四, 四月 25, 2024
Symposium, WHS, Patient, SAWC, Wound, European Wound Management Association, Wound healing, EWMA, Nursing

YAVNE, Israel, April 25, 2024 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), the global leader in next-generation enzymatic therapeutics for tissue repair, announced today that recent clinical data from EscharEx® Phase II studies will be presented throughout May 2024 at the largest, most prestigious annual meetings in the field of chronic wound care: the European Wound Management Association (EWMA), the Wound Healing Society (WHS), and the Symposium on Advanced Wound Care (SAWC).

Key Points: 
  • The oral presentations on EscharEx will include:
    Comparative data of EscharEx vs. SANTYL® that demonstrate EscharEx’s superiority over the current leading enzymatic debridement agent
    New analyses from the ChronEx phase II study, showing high correlation between wound bed preparation and wound healing
    These data indicate that EscharEx could substantially improve wound care for patients with debilitating chronic wounds, providing significant benefits over the current standard of care.
  • Additionally, the findings support the design and endpoints of the upcoming Phase III study, which is expected to begin in the second half of 2024.
  • "We are delighted to present the results of additional analyses from EscharEx Phase II studies in chronic hard-to-heal wounds, including the positive comparative data with SANTYL®, the current dominant standard of care for enzymatic debridement," said Dr. Robert J. Snyder, Chief Medical Officer of MediWound.
  • "With its robust efficacy, favorable safety profile, and multimodal mechanistic effects demonstrated in these Phase II studies, we believe that EscharEx can significantly advance wound care and has the potential to become a major player in the global wound care market."

MPM Medical Launching New Wound Care Products and Branding

Retrieved on: 
星期二, 四月 23, 2024
Aloe, Wound healing, Safety, CPH, Abstract, Aloe vera, Granulation tissue, Acid, CIC, WHS, Medicine, MPH, SAWC, Wound, Associate, Lidocaine, Nursing

MESQUITE, Texas, April 23, 2024 /PRNewswire/ -- MPM Medical, a pioneer in the advanced wound care industry, will participate in the 2024 Symposium on Advanced Wound Care (SAWC) Spring | Wound Healing Society (WHS) held May 14-18 in Orlando. As the largest gathering of multidisciplinary wound care clinicians in the United States, this year's symposium will be a momentous event for MPM Medical.

Key Points: 
  • MESQUITE, Texas, April 23, 2024 /PRNewswire/ -- MPM Medical , a pioneer in the advanced wound care industry, will participate in the 2024 Symposium on Advanced Wound Care (SAWC) Spring | Wound Healing Society (WHS) held May 14-18 in Orlando.
  • As the largest gathering of multidisciplinary wound care clinicians in the United States, this year's symposium will be a momentous event for MPM Medical.
  • Attendees are invited to stop by the MPM Medical booth #633 for product demonstrations from our certified wound care experts or to request product samples.
  • In addition to the expanded range of advanced wound care products, MPM Medical's booth will be showcasing the company's new corporate branding and tagline, Medical Products that Matter™.

Kane Biotech Announces Fourth Quarter and Full Year 2023 Financial Results

Retrieved on: 
星期二, 三月 26, 2024
Diabetic foot, Financial statement, PIN, Ulcer, Symposium, Sale, KNE, Pivot, Credit, Leg, SAWC, US FDA, Patent, FDA, Government, Food

WINNIPEG, Manitoba, March 26, 2024 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX- V:KNE; OTCQB:KNBIF) (the “Company” or “Kane Biotech”) today announces its fourth quarter and full year 2023 financial results.

Key Points: 
  • WINNIPEG, Manitoba, March 26, 2024 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX- V:KNE; OTCQB:KNBIF) (the “Company” or “Kane Biotech”) today announces its fourth quarter and full year 2023 financial results.
  • On December 20, 2023, Kane Biotech announced that it received a non-binding offer for its interest in STEM Animal Health.
  • Gross profit for the fourth quarter of 2023 was $398,234, an increase of 24% compared to $320,653 for the fourth quarter ended December 31, 2022.
  • Loss for the fourth quarter of 2023 was ($1,611,894), an increase of 92% compared to ($838,150) for the quarter ended December 31, 2022.

MediWound Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Company Update

Retrieved on: 
星期四, 三月 21, 2024
Burn, Tax, Debridement, Patient, EWMA, Bank statement, Eschar, Investment, SAWC, Therapy, Depreciation, European Commission, Phase, BCC, Research, Supplement, Wound, EMA, GMP, HERE, Safety, CMS, BLA, Eastern Time Zone, Food, Bromelain (pharmacology), WBP, Development, PMI, WHS, Adjustment, FDA, BMCI, Forecasting, Symposium, Incidence, BSV, Basal-cell carcinoma, Operating cost, European Wound Management Association, Table, Event, Medicare, Pharmaceutical industry

YAVNE, Israel, March 21, 2024 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), the global leader in next-generation enzymatic therapeutics for tissue repair, today announced financial results for the fourth quarter and full year ended December 31, 2023, and provided a corporate update.

Key Points: 
  • Revenue: Revenue for the fourth quarter 2023 was $5.3 million, compared to $11.6 million in the fourth quarter of 2022.
  • Research and development expenses in the fourth quarter 2023 were $1.8 million compared to $2.7 million in the fourth quarter of 2022.
  • Selling, general, and administrative expenses in the fourth quarter 2023 were $2.8 million, compared to $3.0 million in the fourth quarter of 2022.
  • Operating Results: Operating loss in the fourth quarter of 2023 was $3.9 million, compared to an operating profit of $2.1 million in the fourth quarter of 2022.